NCI/CIRB A081105 RANDOMIZED STUDY OF ERLOTINIB VS OBSERVATION IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)

IRB16-023
Cancer, Cancer - Lung
John McCann, MD

Damour Center for Cancer Care

3350 Main Street
Springfield, MA 01199

The purpose of this study is to compare any good/bad effects patients may have when treated with standard treatment against patients who are treated with standard treatment plus erlotinib. You are being asked to take part in this research study because you have early stage non-small cell lung cancer that was surgically removed and may have been treated with chemotherapy and/or radiation. The tumor removed has a mutation of a gene called EGFR.
COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)MUTANT NON-SMALL CELL LUNG CANCER
Betsy Lopez
413-794-4154